Atypical Parkinson’s disease is a group of neurodegenerative brain disorders that look like Parkinson’s disease on the surface but behave differently, progress faster, and respond poorly to standard Parkinson’s medications. The term covers four main conditions: progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies (DLB). Each has its own pattern of symptoms, but they share a core problem: the brain’s dopamine-producing cells deteriorate, causing stiffness, slowness, and difficulty with movement, much like typical Parkinson’s. The critical difference is that atypical forms also damage other brain systems, producing symptoms that standard Parkinson’s disease does not.
How It Differs From Typical Parkinson’s
In typical Parkinson’s disease, symptoms usually start on one side of the body, include a slow “pill-rolling” tremor at rest, and improve significantly with levodopa, the main medication used to replace lost dopamine. Atypical parkinsonism breaks these patterns in several ways. Movement problems tend to appear more symmetrically, affecting both sides of the body early on. The classic resting tremor is often absent or replaced by a different type of tremor. And symptoms that don’t involve movement, like cognitive decline, severe blood pressure drops, or problems with eye movement, show up earlier and more prominently than they would in standard Parkinson’s.
The most telling difference is how the body responds to levodopa. In one study measuring motor improvement after levodopa treatment, roughly 89% of people with PSP and 77% of people with MSA showed no meaningful response at all. Only about 4% of PSP patients experienced a good improvement. This poor medication response is one of the first clinical red flags that something other than typical Parkinson’s may be going on.
Progressive Supranuclear Palsy (PSP)
PSP is the most common form of atypical parkinsonism. Its hallmark is difficulty with vertical eye movements, particularly looking downward. Early on, this can cause problems reading, navigating stairs, or making eye contact during conversation. Falls are another defining feature. People with PSP tend to fall backward, often without trying to catch themselves, and these unprovoked falls typically begin within the first three years of the disease.
About 40% of PSP cases follow a pattern called Richardson’s syndrome, which involves symmetric stiffness centered in the trunk and neck rather than the limbs, along with the characteristic eye movement problems. Another 20% initially look almost identical to typical Parkinson’s, with one-sided symptoms that even respond partially to levodopa, making early diagnosis difficult. These cases are only recognized as PSP when eye movement problems or severe balance issues develop later. A frontal lobe syndrome is also common, showing up as apathy, difficulty planning and organizing, and sometimes a curious inability to stop clapping after being asked to clap three times (called the “applause sign”).
Multiple System Atrophy (MSA)
MSA stands out because it attacks the autonomic nervous system, the part of the brain and spinal cord that controls automatic body functions like blood pressure, bladder control, and sexual function. These problems aren’t just side effects; they’re required for a diagnosis. The most measurable is neurogenic orthostatic hypotension, where blood pressure drops sharply when standing up, causing dizziness or fainting. A drop of 20 points or more in the top blood pressure number within three minutes of standing is the diagnostic threshold.
MSA comes in two subtypes. MSA-P is dominated by Parkinson’s-like stiffness and slowness, while MSA-C primarily affects coordination and balance (cerebellar symptoms). In MSA-P, the movement problems tend to be more evenly distributed across both sides of the body than in typical Parkinson’s, and the tremor, when present, is usually a jerky, irregular tremor that occurs when holding a posture rather than the slow resting tremor of Parkinson’s. Certain distinctive features can help clinicians confirm MSA with high accuracy: involuntary facial or jaw muscle spasms, deep involuntary sighing breaths, cold and discolored hands and feet, and hand or foot contractures. When any of these features appear during a person’s lifetime, the likelihood of the diagnosis being correct exceeds 90%.
Corticobasal Degeneration (CBD)
CBD is the rarest of the four and perhaps the most unusual in how it presents. It typically starts with profound difficulty using one hand or arm, and this one-sidedness remains a defining feature throughout the disease. The affected limb becomes increasingly stiff, and the hand may curl into a fist or adopt postures that the person cannot voluntarily control.
What makes CBD particularly distinctive is the range of higher-brain-function symptoms it produces. Apraxia, the inability to perform familiar purposeful movements despite having normal strength, is common. Someone with CBD might be unable to use a key or brush their teeth, not because of weakness, but because the brain can no longer plan the sequence of movements. Some people develop what’s called the alien limb phenomenon, a deeply unsettling experience where one’s own arm or hand moves on its own or feels like it belongs to someone else. Cortical sensory loss is another feature: the hand can still feel touch, but the brain can’t interpret what it’s feeling, so tasks like identifying an object by touch or recognizing a number drawn on the palm become impossible. Like the other atypical syndromes, CBD is resistant to levodopa.
Dementia With Lewy Bodies (DLB)
DLB shares the same underlying protein deposits (Lewy bodies) found in typical Parkinson’s disease, but the key difference is timing. In DLB, cognitive problems develop before or within one year of movement symptoms appearing. If someone has Parkinson’s for years before developing dementia, that’s classified as Parkinson’s disease dementia instead. This “one-year rule” is the main clinical boundary between the two, though many researchers view them as different points on the same spectrum of Lewy body disease.
The cognitive symptoms in DLB have a distinctive flavor. Attention and alertness fluctuate dramatically, sometimes within the same day. Vivid, detailed visual hallucinations are common and often involve seeing people or animals. These hallucinations can appear early, sometimes before any movement difficulties, and their presence is a strong diagnostic clue.
How Atypical Parkinsonism Is Diagnosed
There is no single test that confirms atypical parkinsonism. Diagnosis relies heavily on clinical observation over time, which is part of what makes these conditions so frustrating for patients and families. Many people are initially diagnosed with typical Parkinson’s disease, only to have the diagnosis revised months or years later when symptoms evolve in unexpected directions.
A brain imaging technique called a DaTscan can detect loss of dopamine-producing cells, which is useful for confirming that a true parkinsonian process is occurring rather than something else mimicking it, like medication side effects or essential tremor. However, DaTscan shows dopamine loss in both typical and atypical parkinsonism, so it cannot distinguish between the two. It’s a helpful ruling-out tool, not a ruling-in tool. MRI scans can sometimes reveal patterns of brain shrinkage specific to certain atypical conditions, but these changes may not appear early in the disease.
The practical reality is that diagnosis often becomes clearer as symptoms progress. Red flags that should prompt reconsideration of a typical Parkinson’s diagnosis include early and severe falls, rapid cognitive decline, prominent hallucinations in the first year, severe autonomic problems like fainting or urinary incontinence, and little or no benefit from levodopa after an adequate trial.
Progression and Life Expectancy
Atypical parkinsonism progresses faster than typical Parkinson’s disease. In a population-based study with a mean starting age of about 72, people with typical Parkinson’s had an expected survival of roughly 9.6 years, while those with atypical parkinsonism averaged 6.1 years. The risk of death was highest in MSA, where the mortality rate was nearly three times that of typical Parkinson’s after adjusting for age. PSP carried about 1.4 times the risk of typical Parkinson’s.
These are averages, and individual experiences vary considerably depending on age at onset, which specific syndrome is involved, and which symptoms dominate. CBD and MSA tend to progress more rapidly, while some forms of PSP can have a slower course, particularly those that initially resemble typical Parkinson’s.
Treatment and Day-to-Day Management
Because levodopa offers little benefit in most atypical cases, treatment focuses on managing specific symptoms and maintaining quality of life for as long as possible. A multidisciplinary approach is the standard of care, combining physical therapy, occupational therapy, speech and language therapy, and psychological support into a coordinated program. These teams typically include movement disorder specialists, neuropsychologists, and specialized nurses working alongside therapists.
Physical therapy plays a particularly important role in addressing balance problems and reducing fall risk, especially in PSP. Speech therapy targets the severe voice and swallowing difficulties that develop in MSA and PSP, where the ability to speak clearly and swallow safely can deteriorate significantly. Occupational therapy helps people adapt their daily routines and home environments as motor function declines. Some specialized inpatient programs offer intensive, structured therapy combining multiple disciplines for several hours per day.
For specific symptoms, medications can help in targeted ways. Blood pressure support for orthostatic hypotension in MSA, medications for bladder dysfunction, and careful management of hallucinations and behavioral changes in DLB all play a role. A trial of levodopa is still commonly attempted, because the small percentage of people who do respond, even partially, benefit from whatever improvement can be gained. The medication is typically tapered off if no benefit is seen after an adequate trial period.